Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanolimumab in Refractory Mycosis Fungoides and Sezary Syndrome
NCT00127881Phase 3Terminated
- Sponsor
- Emergent BioSolutions
- Start
- Jul 2005
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of zanolimumab in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Emergent BioSolutions. Primary endpoint: Physician's Global Assessment. Started Jul 2005; status: terminated.
02
Drugs
zanolimumab
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT00127881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127881.